Richard G. Stock, MD, presented “Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaque” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
How to cite: Stock, Richard G. “Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaque.” October 17, 2024. Accessed Nov 2025. https://grandroundsinurology.com/hydrogel-rectal-spacer-radiopaque-vs-non-radiopaque/
Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaque – Summary
Richard G. Stock, MD, explores the role of rectal spacers in reducing gastrointestinal toxicity during prostate cancer radiotherapy. In this 21-minute presentation, Dr. Stock highlights the significant impact of radiation on rectal tissues, where standard treatment can lead to grade 2+ toxicities, including proctitis, rectal bleeding, and discomfort.
Rectal spacers create a physical separation between the prostate and rectum, minimizing radiation exposure. Dr. Stock shares images demonstrating how hydrogel injections effectively push the prostate away from the rectum, reducing rectal dose and associated toxicities.
Dr. Stock shares early research on hyaluronic acid and polyethylene glycol-based hydrogels, validating their ability to lower rectal radiation exposure and mitigate side effects. Advanced versions, such as SpaceOAR VueTM, incorporate contrast agents, enhancing visibility for precise placement and treatment planning.
While spacer insertion requires skill, the proper technique ensures optimal separation and prevents complications. Clinical data suggest that rectal spacers should become an important component in prostate cancer radiotherapy, ensuring safer, more effective treatment.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.
